A model to study drug effects on lymphoma and normal cell populations using the AKR/J mouse

• Published in: Leukemia research Vol. 6; no. 2; pp. 269 - 279
• Main Authors: Schwartz, G.N., Biegel, J.A., Boggs, S.S.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 1982
• Subjects: Animals; Carmustine - therapeutic use; Cell Line; Disease Models, Animal; Germanium - therapeutic use; Karyotyping; Leukemia, Experimental - drug therapy; Lymphoma - drug therapy; Lymphoma - genetics; Mice; Mice, Inbred AKR - physiology; Neoplasm Transplantation; Organometallic Compounds; Spiro Compounds - therapeutic use; HBSS; SG; MI; BCNU
• ISSN: 0145-2126; 1873-5835
• DOI: 10.1016/0145-2126(82)90033-9

The existence of an AKR subline, AKR(Rb6.15)1A1d, with a chromosome marker provided a means to differentiate between proliferating lymphoma and normal cell populations within a single animal. An AKR(Rb6.15)1A1d lymphoma cell line has been maintained for 6 yr by serial passage in AKR/J recipients. The mice die in 7 ± 2.0 days with evidence of extensive infiltration of the tissues by lymphoma cells. Cytogenetic analysis showed that approx. 1% of the metaphase cells in the bone marrow of mice at day 1 of the lymphoma passage were of the AKR(Rb6.15)1A1d donor-type. This increased to 54% by day 4 and 96% by day 6. The number of donor-type metaphase cells per humerus increased from 3.4 ± 0.29 ( × 10 3) at day 1 to 2.0 ± 0.49 ( × 10 5) at day 4 with a concomitant decrease in the number of non-lymphoma host-type metaphase cells. The population doubling time of donor-type metaphase cells per humerus was 1.2 ± 1.4 h. At day 4 there was a significant decrease in the percentage of donor-type metaphase cells in mice that had been treated with BCNU (19.0 ± 5.85%) or spirogermanium (38.6 ± 5.85%) 24 h earlier. For BCNU treated animals, this also represented a decrease to 4.4 ± 1.1( × 10 4) donor-type metaphase cells per humerus.